Bruker (BRKR) return on equity (ROE)

Return on equity · fiscal 2025
-0.3%

Bruker (BRKR) earned a return on equity of -0.3% in fiscal 2025 (the year ended December 31, 2025). That is 6.6 percentage points lower than the 6.2% of fiscal 2024. Figures as of 18 Nov 2026, 06:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-0.3%
Change on fiscal 2024
−6.6 pts
Highest on record
30.2%fiscal 2023
Lowest on record
-0.3%fiscal 2025
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Bruker return on equity (ROE), in more detail

Across the 17 fiscal years on record (2009–2025), the highest was 30.2% in fiscal 2023 and the lowest -0.3% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 16 earlier fiscal years on record, whose median is 17.3%.

History · 17 fiscal years

Return on equity by fiscal year

Bruker return on equity (ROE), year by year

Bruker (BRKR) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-0.3% 6.6 pts down
20246.2% 24.0 pts down
202330.2% 4.0 pts up
202226.2% 0.3 pts up
202125.9% 9.5 pts up
202016.4% 5.3 pts down
201921.7% 1.7 pts up
201820.0% 9.2 pts up
201710.8% 11.5 pts down
201622.4% 8.4 pts up
201514.0% 6.6 pts up
20147.4% 2.1 pts down
20139.5% 1.5 pts down
201211.0% 3.9 pts down
201114.9% 3.3 pts down
201018.2% 1.2 pts down
200919.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Bruker and comparable companies
CompanyReturn on equityFiscal year
Spyre Therapeutics SYRE-21.7%2025
Qiagen QGEN11.2%2025
Insulet PODD16.3%2025
Bruker BRKR-0.3%2025
Globus Medical GMED11.8%2025
Madrigal Pharmaceuticals MDGL-47.8%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BRKR

Bruker, figure by figure

Bruker (BRKR) overview: price, valuation and scorecardAll health care companies by market value

Bruker return on equity (ROE): questions and answers

What is Bruker's return on equity?

Bruker (BRKR) earned a return on equity of -0.3% in fiscal 2025 (the year ended December 31, 2025). That is 6.6 percentage points lower than the 6.2% of fiscal 2024.

Is Bruker's return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 16 earlier fiscal years on record, whose median is 17.3%.

What are the highest and lowest return on equity figures on record for Bruker?

Across the 17 fiscal years on record (2009–2025), the highest was 30.2% in fiscal 2023 and the lowest -0.3% in fiscal 2025.

How is Bruker's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bruker (BRKR) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/BRKR/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.